Clinical Inquiry: Does qHPV vaccine prevent anal intraepithelial neoplasia and condylomata in men?

J Fam Pract. 2015 Sep;64(9):581-3.

Abstract

Yes. Quadrivalent human papillomavirus (qHPV) vaccine reduces rates of anal intraepithelial neoplasia (AIN) by 50% to 54%, and persistent anal infection by 59%, associated with the 4 types of HPV in the vaccine (6, 11, 16, and 18) in young men who have sex with men (MSM); it also reduces external genital lesions by 66%, and persistent HPV infection associated with the same 4 HPV types by 48 to 59% in all young men, heterosexual men, and MSM.

Publication types

  • Review

MeSH terms

  • Anus Diseases / prevention & control
  • Anus Neoplasms / prevention & control*
  • Carcinoma in Situ / prevention & control*
  • Condylomata Acuminata / prevention & control*
  • Humans
  • Male
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Vaccines*

Substances

  • Papillomavirus Vaccines